Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,589 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study.
Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang MH, Sakai N, Fukui M, Nakaji H, Morita M, Mio T, Yasuda T, Sugita T, Hirai T. Fujimoto D, et al. Among authors: morita m. Lung Cancer. 2018 May;119:14-20. doi: 10.1016/j.lungcan.2018.02.017. Epub 2018 Mar 2. Lung Cancer. 2018. PMID: 29656747
Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy.
Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Hata T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang MH, Sakai N, Fukui M, Nakaji H, Morita M, Mio T, Yasuda T, Sugita T, Hirai T. Fujimoto D, et al. Among authors: morita m. J Thorac Oncol. 2019 Mar;14(3):468-474. doi: 10.1016/j.jtho.2018.10.167. Epub 2018 Nov 20. J Thorac Oncol. 2019. PMID: 30468872 Free article.
Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
Edahiro R, Kanazu M, Kurebe H, Mori M, Fujimoto D, Taniguchi Y, Suzuki H, Hirano K, Yokoyama T, Morita M, Fukuda Y, Uchida J, Makio T, Tamiya M. Edahiro R, et al. Among authors: morita m. PLoS One. 2019 Jul 31;14(7):e0220570. doi: 10.1371/journal.pone.0220570. eCollection 2019. PLoS One. 2019. PMID: 31365588 Free PMC article.
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).
Tamiya M, Tamiya A, Hosoya K, Taniguchi Y, Yokoyama T, Fukuda Y, Hirano K, Matsumoto H, Kominami R, Suzuki H, Hirashima T, Uchida J, Morita M, Kanazu M, Sawa N, Kinoshita Y, Hara S, Kumagai T, Fujimoto D. Tamiya M, et al. Among authors: morita m. Invest New Drugs. 2019 Dec;37(6):1266-1273. doi: 10.1007/s10637-019-00843-y. Epub 2019 Aug 7. Invest New Drugs. 2019. PMID: 31392549
A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302.
Ikeda S, Yoshioka H, Kaneda T, Yokoyama T, Niwa T, Sone N, Ishida T, Morita M, Tomioka H, Komaki C, Hirabayashi M, Hasegawa Y, Noguchi T, Nakano Y, Sakaguchi C, Yoshimura K, Hirai T. Ikeda S, et al. Among authors: morita m. Oncology. 2019;97(6):327-333. doi: 10.1159/000501967. Epub 2019 Aug 14. Oncology. 2019. PMID: 31412347 Clinical Trial.
3,589 results